SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$88.98
+1.98%Aug 26, 2026, 12:22 UTC
Spyre Therapeutics shares fell 12.35% in after-hours trading after its mid-stage clinical trial for a rheumatoid arthritis drug failed to meet internal criteria for advancing as a monotherapy.
Aug 7, 2026, 20:05 UTC
Spyre Therapeutics' Compensation Committee approved equity inducement awards of stock options for 19,436 shares and 6,186 restricted stock units to four non-executive employees on August 3, 2026, as material inducements to their employment acceptance.
Source:Aug 5, 2026, 16:11 UTC
Spyre reported its Q2 2026 financial results, with a narrower-than-expected loss.
Source:Aug 4, 2026, 20:02 UTC
Spyre Therapeutics announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial, demonstrating best-in-class efficacy potential and a safety profile consistent with in-class comparators.
Source:Jul 2, 2026, 20:05 UTC
Spyre Therapeutics granted stock options and restricted stock units to six non-executive employees as inducement awards to accept employment.
Source:Jun 15, 2026, 12:28 UTC
Spyre Therapeutics announced that its experimental bowel disease drug met the main goal of significantly reducing disease severity in a mid-stage trial.
Source:Jun 3, 2026, 12:00 UTC
Spyre Therapeutics completed enrollment in the SKYWAY basket trial evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA.
Source: